Comparing adult height gain and menarcheal age between girls with central precocious puberty treated with gonadotropin-releasing hormone agonist alone and those treated with combined growth hormone therapy
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to investigate the outcomes of gonadotropin-releasing hormone agonist (GnRHa) therapy with or without growth hormone (GH) therapy for girls with idiopathic central precocious puberty (CPP). Methods: The medical records of 166 girls diagnosed with CPP from 2002 to 2017 were retrospectively reviewed. All included patients were treated with GnRHa for ≥36 months. Changes in height standard deviation score (SDS) for bone age, chronological age (CA), and predicted adult height (PAH) were assessed for the first three years of treatment. The final height gain SDS was calculated as the difference between the initial PAH SDS and adult height (AH) SDS; these were then compared between the GnRHa group (group A, n=135) and the combined GnRHa/GH group (group B, n=31). Results: The initial mean CA was 7.89 years. The mean menarcheal age was 13.12 years (group A, 13.1±0.99; group B, 13.18±0.58 years; P=0.755). PAH SDS at the start of GnRHa treatment and AH SDS were significantly lower in group B than in group A (PAH SDS: -2.20±0.83 vs. -3.19±0.84, P<0.001; AH SDS: 0.18±084 vs. -0.30±0.66, P=0.021). The increase in PAH SDS was higher in group B than in group A for the first three years of GnRHa treatment (1.66±0.66 vs. 2.35±0.93, P<0.001). The height gain SDS was significantly higher in group B than in group A (2.5±0.75 vs. 2.93±1.02, P=0.048). Younger age, higher PAH at the start of treatment, and a greater increase in PAH SDS during the first year of GnRHa treatment positively affected AH. Conclusion: The combined GH group had more additional height gain than the GnRHa-alone group.
Abstract
Purpose: This study aimed to investigate the outcomes of gonadotropin-releasing hormone agonist (GnRHa) therapy with or without growth hormone (GH) therapy for girls with idiopathic central precocious puberty (CPP). Methods: The medical records of 166 girls diagnosed with CPP from 2002 to 2017 were retrospectively reviewed. All included patients were treated with GnRHa for ≥36 months. Changes in height standard deviation score (SDS) for bone age, chronological age (CA), and predicted adult height (PAH) were assessed for the first three years of treatment. The final height gain SDS was calculated as the difference between the initial PAH SDS and adult height (AH) SDS; these were then compared between the GnRHa group (group A, n=135) and the combined GnRHa/GH group (group B, n=31). Results: The initial mean CA was 7.89 years. The mean menarcheal age was 13.12 years (group A, 13.1±0.99; group B, 13.18±0.58 years; P=0.755). PAH SDS at the start of GnRHa treatment and AH SDS were significantly lower in group B than in group A (PAH SDS: -2.20±0.83 vs. -3.19±0.84, P<0.001; AH SDS: 0.18±084 vs. -0.30±0.66, P=0.021). The increase in PAH SDS was higher in group B than in group A for the first three years of GnRHa treatment (1.66±0.66 vs. 2.35±0.93, P<0.001). The height gain SDS was significantly higher in group B than in group A (2.5±0.75 vs. 2.93±1.02, P=0.048). Younger age, higher PAH at the start of treatment, and a greater increase in PAH SDS during the first year of GnRHa treatment positively affected AH. Conclusion: The combined GH group had more additional height gain than the GnRHa-alone group.
참고문헌 (33)
- Partsch CJ, "Pathogenesis and epidemiology of precocious puberty. Effects of exogenous oestrogens", Hum Reprod Update, 7, pp.292~302 (2001)
- Su PH, "A study of anthropomorphic and biochemical characteristics in girls with central precocious puberty and thelarche variant", J Pediatr Endocrinol Metab, 21, pp.213~220 (2008)
- Cesario SK, "Precocious puberty: a comprehen-sive review of literature", J Obstet Gynecol Neonatal Nurs, 36, pp.263~274 (2007)
- Chauhan A, "Disorders of childhood growth and development: precocious puberty", FP Essent, 410, pp.25~31 (2013)
- Carel JC, "Consensus statement on the use of gonadotro-pin-releasing hormone analogs in children", Pediatrics, 123, pp.e752~e762 (2009)
- Partsch CJ, "Management and outcome of central precocious puberty", Clin Endocrinol (Oxf ), 56, pp.129~148 (2002)
- Crowley WF Jr, "Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty", J Clin Endocrinol Metab, 52, pp.370~372 (1981)
- Parker KL, "Depot leuprolide acetate for treatment of precocious puberty", J Clin Endocrinol Metab, 69, pp.689~691 (1989)
- Allali S, "Predicting the adult height of girls with central precocious puberty", Med Sci Monit, 17, pp.PH41~PH48 (2011)
- Clemons RD, "Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty", Am J Dis Child, 147, pp.653~657 (1993)
- Kauli R, "Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method", Horm Res, 47, pp.54~61 (1997)
- Lanes R, "Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs", J Pediatr Endocrinol Metab, 17, pp.759~766 (2004)
- Léger J, "Do all girls with apparent idiopathic precocious puberty require gonadotro-pin-releasing hormone agonist treatment?", J Pediatr, 137, pp.819~825 (2000)
- Lee PA, "Efficacy of leuprolide acetate 1-month depot for central precocious puberty (CPP): growth outcomes during a prospective, longitudinal study", Int J Pediatr Endocrinol, 2011, pp.7~ (2011)
- 권은별, "Changes in the Predicted Adult Height after Gonadotropin-Releasing Hormone Agonist Treatment in Girls with Idiopathic True Precocious Puberty", Annals of Pediatric Endocrinology & Metabolism, 17(3), pp.160~168 (2012), 대한소아내분비학회
- Müller J, "Hormonal changes during GnRH analogue therapy in children with central precocious puberty", J Pediatr Endocrinol Metab, 13(Suppl 1), pp.739~746 (2000)
- Wu JM, "Gene expression related to growth axis and gonadal axis in puberty rats", Zhong Xi Yi Jie He Xue Bao, 1, pp.35~38 (2003)
- Cara JF, "Growth hormone deficiency impedes the rise in plasma insulin-like growth factor I levels associated with precocious puberty", J Pediatr, 115, pp.64~68 (1989)
- Pasquino AM, "Combined treatment with gonadotropin-releasing hormone analog and growth hormone in central precocious puberty", J Clin Endocrinol Metab, 81, pp.948~951 (1996)
- Pasquino AM, "Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone", J Clin Endocrinol Metab, 84, pp.449~452 (1999)
- Kohn B, "Combined use of growth hormone and gonadotropin-releasing hormone analogues:the national cooperative growth study experience", Pediatrics, 104(4 Pt 2), pp.1014~1018 (1999)
- Pyle SI, "Radiographic atlas of skeletal development of the hand and wrist" (1959), Stanford University Press
- Bayley N, "Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards", J Pediatr, 40, pp.423~441 (1952)
- "2017 Korean children and adolescents growth standard: commentary for the development of 2017 growth chart" (2018)[URL]
- Oostdijk W, "Long-term results with a slow-release gonadotrophin-releasing hormone agonist in central precocious puberty. Dutch-German Precocious Puberty Study Group", Acta Paediatr Scand Suppl, 372, pp.39~45 (1991)
- Pucarelli I, "Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution", J Pediatr Endocrinol Metab, 16, pp.1005~1010 (2003)
- Mul D, "Final height after treatment of early puberty in short adopted girls with gonadotrophin releasing hormone agonist with or without growth hormone", Clin Endocrinol (Oxf), 63, pp.185~190 (2005)
- Saggese G, "Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis", Acta Paediatr, 84, pp.299~304 (1995)
- Mul D, "Gonadotrophin releasing hormone agonist treatment with or without recombinant human GH in adopted children with early puberty", Clin Endocrinol (Oxf), 55, pp.121~129 (2001)
- Tuvemo T, "Growth hormone treatment during suppression of early puberty in adopted girls. Swedish Growth Hormone Advisory Group", Acta Paediatr, 88, pp.928~932 (1999)
- 정모경, "Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone", Annals of Pediatric Endocrinology & Metabolism, 19(4), pp.214~219 (2014), 대한소아내분비학회
- Gyon Y, "Age at menarche and near final height after treatment with gonadotropin-releasing hormone agonist alone or combined with growth hormone in Korean girls with central precocious puberty", Clin Pediatr Endocrinol, 24, pp.175~183 (2015)
- Volta C, "Combined therapy with luteinizing hormone releasing hormone agonist (LHRHa) and growth hormone (GH) in central precocious puberty", Acta Biomed, 76, pp.73~78 (2005)